cardiotomskСибирский журнал клинической и экспериментальной медициныSiberian Journal of Clinical and Experimental Medicine2713-29272713-265XTSU publishing10.29001/2073-8552-2022-37-2-35-40cardiotomsk-1417Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESГипертрофическая кардиомиопатия: современный взгляд на вопросы диагностики и ведения пациентов (обзор)Hypertrophic cardiomyopathy: A modern view on the diagnosis and management of patients (review)https://orcid.org/0000-0002-7384-9705ЗахарьянЕ. А.ZakharyanE. A.

Захарьян Елена Аркадьевна, канд. мед. наук, доцент кафедры внутренней медицины № 1

295051, Российская Федерация, Республика Крым, Симферополь, б-р Ленина, 5/7

Elena A. Zakharyan, Cand. Sci. (Med.), Associate Professor,Department of Internal Medicine No. 1

5/7, Lenin blvd., Simferopol, 295051, Republic of Crimea, Russian Federation

locren@yandex.ruhttps://orcid.org/0000-0001-9224-4464СалиеваГ. М.SalievaG. M.

Салиева Гюзель Мустафаевна, студент, первый медицинский факультет

295051, Российская Федерация, Республика Крым, Симферополь, б-р Ленина, 5/7

Gyuzel M. Salieva, Student, First Medical Faculty

5/7, Lenin blvd., Simferopol, 295051, Republic of Crimea, Russian Federation

gyuzelsalieva@gmail.comhttps://orcid.org/0000-0003-0978-975XТерземанИ. Е.TerzemanI. E.

Терземан Ирина Евгеньевна, студент, первый медицинский факультет

295051, Российская Федерация, Республика Крым, Симферополь, б-р Ленина, 5/7

Irina E. Terzeman, Student, First Medical Faculty

5/7, Lenin blvd., Simferopol, 295051, Republic of Crimea, Russian Federation

irinaterzeman.it1998@gmail.comКрымский федеральный университет имени В.И. Вернадского, Медицинская академия имени С.И. ГеоргиевскогоРоссияV. I. Vernadsky Crimean Federal University, Crimea State Medical University named after S. I. GeorgievskyRussian Federation2022140720223723540Copyright © Захарьян Е.А., Салиева Г.М., Терземан И.Е., 20222022Захарьян Е.А., Салиева Г.М., Терземан И.Е.Zakharyan E.A., Salieva G.M., Terzeman I.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sibjcem.ru/jour/article/view/1417

Гипертрофическая кардиомиопатия (ГКМП) представляет собой генетически детерминированное заболевание с высокой распространенностью и манифестацией в возрасте 30–40 лет. В настоящее время наиболее эффективными методами лечения являются расширенная миоэктомия и септальная миоэктомия по Morrow. Однако наличие частых послеоперационных осложнений и ограничений к применению данных методов у некоторых групп пациентов является причиной для усовершенствования имеющихся способов лечения, а также поиска новых фармакологических подходов. Одним из наиболее перспективных направлений консервативной терапии представляется изучение специфического низкомолекулярного аллостерического ингибитора миозин-аденозинтрифосфотазы (мавакамтена). Клинические исследования эффективности и безопасности этого препарата продолжаются по сей день, и при успешном их завершении он может быть включен в протокол фармакотерапии ГКМП.

Hypertrophic cardiomyopathy (HCM) is a genetically determined disease with a high prevalence and manifestation at the age of 30–40 years. Currently available most effective treatments are extended myectomy and Morrow septal myectomy. However, the frequent occurrence of postoperative complications and restrictions to the use of these methods in certain groups of patients provides rationale for the improvement of the existing treatment methods and search for new pharmacological approaches. One of the most promising areas of conservative therapy is the study of a specific small-molecule allosteric inhibitor of myosinadenosine triphosphatase (mavacamten). Clinical studies of the efficacy and safety of this drug continue to this day, and if they are successfully completed, the drug may be included in the pharmacotherapy protocol for HCM.

гипертрофическая кардиомиопатиясептальная миоэктомиярасширенная миоэктомияспиртовая септальная аблациямавакамтенhypertrophic cardiomyopathyseptal myectomyextended myectomyalcohol-based septal ablationmavacamtenReferencesГипертрофическая кардиомиопатия: клинические рекомендации. М.: Министерство здравоохранения Российской Федерации; 2020:151.Hypertrophic cardiomyopathy: Сlinical recommendations. Moscow: Ministry of Health of the Russian Federation; 2020:151. (In Russ.).Teare D. Asymmetrical hypertrophy of the heart in young adults. Br. Heart J. 1958;20(1):1–8. DOI: 10.1136/hrt.20.1.1.Teare D. Asymmetrical hypertrophy of the heart in young adults. Br. Heart J. 1958;20(1):1–8. DOI: 10.1136/hrt.20.1.1.Antunes M.O., Scudeler T.L. Hypertrophic cardiomyopathy. Int. J. Cardiol. Heart Vasc. 2020;27:100503. DOI: 10.1016/j.ijcha.2020.100503.Antunes M.O., Scudeler T.L. Hypertrophic cardiomyopathy. Int. J. Cardiol. Heart Vasc. 2020;27:100503. DOI: 10.1016/j.ijcha.2020.100503.Hollman A., Goodwin J.F., Teare D. A family with obstructive cardiomyopathy. Br. Heart. J. 1960;22:449–456. DOI: 10.1136/hrt.22.4.449.Hollman A., Goodwin J.F., Teare D. A family with obstructive cardiomyopathy. Br. Heart. J. 1960;22:449–456. DOI: 10.1136/hrt.22.4.449.Ingles J., Goldstein J., Thaxton C., Caleshu C., Corty E.W., Crowley S.B. et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. Circ. Genom. Precis. Med. 2019;12(2):e002460. DOI: 10.1161/CIRCGEN.119.002460.Ingles J., Goldstein J., Thaxton C., Caleshu C., Corty E.W., Crowley S.B. et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. Circ. Genom. Precis. Med. 2019;12(2):e002460. DOI: 10.1161/CIRCGEN.119.002460.Solomon S.D., Geisterfer-Lowrance A.A., Vosberg H.P., Hiller G., Jarcho J.A., Morton C.C. et al. A locus for familial hypertrophic cardiomyopathy is closely linked to the cardiac myosin heavy chain genes, CRI-L436, and CRI-L329 on chromosome 14 at q11-q12. Am. J. Hum. Genet. 1990;47(3):389–394.Solomon S.D., Geisterfer-Lowrance A.A., Vosberg H.P., Hiller G., Jarcho J.A., Morton C.C. et al. A locus for familial hypertrophic cardiomyopathy is closely linked to the cardiac myosin heavy chain genes, CRI-L436, and CRI-L329 on chromosome 14 at q11-q12. Am. J. Hum. Genet. 1990;47(3):389–394.Mazzarotto F., Girolami F., Boschi B., Barlocco F., Tomberli A., Baldini K. et al. Defining the diagnostic effectiveness of genes for inclusion in panels:The experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center. Genet. Med. 2019;21(2):284–292. DOI: 10.1038/s41436-018-0046-0.Mazzarotto F., Girolami F., Boschi B., Barlocco F., Tomberli A., Baldini K. et al. Defining the diagnostic effectiveness of genes for inclusion in panels: The experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center. Genet. Med. 2019;21(2):284–292. DOI: 10.1038/s41436-018-0046-0.Arif M., Nabavizadeh P., Song T., Desai D., Singh R., Bazrafshan S. et al. Genetic, clinical, molecular, and pathogenic aspects of the South Asian-specific polymorphic MYBPC3Δ25bp variant. Biophys. Rev. 2020;12(4):1065–1084. DOI: 10.1007/s12551-020-00725-1.Arif M., Nabavizadeh P., Song T., Desai D., Singh R., Bazrafshan S. et al. Genetic, clinical, molecular, and pathogenic aspects of the South Asian-specific polymorphic MYBPC3Δ25bp variant. Biophys. Rev. 2020;12(4):1065–1084. DOI: 10.1007/s12551-020-00725-1.Mattos B.P. Genetic bases of hypertrophic cardiomyopathy. Arq. Bras. Cardiol. 2002;78(3):323–340. DOI: 10.1590/s0066-782x2002000300009.Mattos B.P. Genetic bases of hypertrophic cardiomyopathy. Arq. Bras. Cardiol. 2002;78(3):323–340. DOI: 10.1590/s0066-782x2002000300009.Madan A., Viswanathan M.C., Woulfe K.C., Schmidt W., Sidor A., Liu T. et al. TNNT2 mutations in the tropomyosin binding region of TNT1 disrupt its role in contractile inhibition and stimulate cardiac dysfunction. Proc. Natl. Acad. Sci. U S A. 2020;117(31):18822–18831. DOI: 10.1073/pnas.2001692117.Madan A., Viswanathan M.C., Woulfe K.C., Schmidt W., Sidor A., Liu T. et al. TNNT2 mutations in the tropomyosin binding region of TNT1 disrupt its role in contractile inhibition and stimulate cardiac dysfunction. Proc. Natl. Acad. Sci. U S A. 2020;117(31):18822–18831. DOI: 10.1073/pnas.2001692117.Pandzic E., Morkel C.A., Li A., Cooke R., Whan R.M., Dos Remedios C.G. Nanomolar ATP binding to single myosin cross-bridges in rigor: A molecular approach to studying myosin ATP kinetics using single human cardiomyocytes. Biophys. Rev. 2020;12(4):1031–1040. DOI: 10.1007/s12551-020-00716-2.Pandzic E., Morkel C.A., Li A., Cooke R., Whan R.M., Dos Remedios C.G. Nanomolar ATP binding to single myosin cross-bridges in rigor: A molecular approach to studying myosin ATP kinetics using single human cardiomyocytes. Biophys. Rev. 2020;12(4):1031–1040. DOI: 10.1007/s12551-020-00716-2.Kuster D.W.D, Lynch T.L., Barefield D.Y., Sivaguru M., Kuffel G., Zilliox M.J. et al. Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy. Cardiovasc. Res. 2019;115(14):1986–1997. DOI: 10.1093/cvr/cvz111.Kuster D.W.D, Lynch T.L., Barefield D.Y., Sivaguru M., Kuffel G., Zilliox M.J. et al. Altered C10 domain in cardiac myosin binding protein- C results in hypertrophic cardiomyopathy. Cardiovasc. Res. 2019;115(14):1986–1997. DOI: 10.1093/cvr/cvz111.Cheng Y., Regnier M. Cardiac troponin structure-function and the influence of hypertrophic cardiomyopathy associated mutations on modulation of contractility. Arch. Biochem. Biophys. 2016;601:11–21. DOI: 10.1016/j.abb.2016.02.004.Cheng Y., Regnier M. Cardiac troponin structure-function and the influence of hypertrophic cardiomyopathy associated mutations on modulation of contractility. Arch. Biochem. Biophys. 2016;601:11–21. DOI: 10.1016/j.abb.2016.02.004.Manivannan S.N., Darouich S., Masmoudi A., Gordon D., Zender G., Han Z. et al. Novel frameshift variant in MYL2 reveals molecular differences between dominant and recessive forms of hypertrophic cardiomyopathy. PLoS Genet. 2020;16(5):e1008639. DOI: 10.1371/journal.pgen.1008639.Manivannan S.N., Darouich S., Masmoudi A., Gordon D., Zender G., Han Z. et al. Novel frameshift variant in MYL2 reveals molecular differences between dominant and recessive forms of hypertrophic cardiomyopathy. PLoS Genet. 2020;16(5):e1008639. DOI: 10.1371/journal.pgen.1008639.Viola H.M., Shah A.A., Johnstone V.P.A., Cserne Szappanos H., Hodson M.P., Hool L.C. Characterization and validation of a preventative therapy for hypertrophic cardiomyopathy in a murine model of the disease. Proc. Natl. Acad. Sci. U S A. 2020;117(37):23113–23124. DOI: 10.1073/pnas.2002976117.Viola H.M., Shah A.A., Johnstone V.P.A., Cserne Szappanos H., Hodson M.P., Hool L.C. Characterization and validation of a preventative therapy for hypertrophic cardiomyopathy in a murine model of the disease. Proc. Natl. Acad. Sci. U S A. 2020;117(37):23113–23124. DOI: 10.1073/pnas.2002976117.Salfati E.L., Spencer E.G., Topol S.E., Muse E.D., Rueda M., Lucas J.R. et al. Re-analysis of whole-exome sequencing data uncovers novel diagnostic variants and improves molecular diagnostic yields for sudden death and idiopathic diseases. Genome Med. 2019;11(1):83. DOI: 10.1186/s13073-019-0702-2.Salfati E.L., Spencer E.G., Topol S.E., Muse E.D., Rueda M., Lucas J.R. et al. Re-analysis of whole-exome sequencing data uncovers novel diagnostic variants and improves molecular diagnostic yields for sudden death and idiopathic diseases. Genome Med. 2019;11(1):83. DOI: 10.1186/s13073-019-0702-2.Brodehl A., Ebbinghaus H., Deutsch M.A., Gummert J., Gärtner A., Ratnavadivel S. et al. Human induced pluripotent stem-cell-derived cardiomyocytes as models for genetic cardiomyopathies. Int. J. Mol. Sci. 2019;20(18):4381. DOI: 10.3390/ijms20184381.Brodehl A., Ebbinghaus H., Deutsch M.A., Gummert J., Gärtner A., Ratnavadivel S. et al. Human induced pluripotent stem-cell-derived cardiomyocytes as models for genetic cardiomyopathies. Int. J. Mol. Sci. 2019;20(18):4381. DOI: 10.3390/ijms20184381.Ватутин Н.Т., Тарадин Г.Г., Марон М.С. Гипертрофическая кардиомиопатия: генетические изменения, патогенез и патофизиология. Российский кардиологический журнал. 2014;(5):35–42. DOI: 10.15829/1560-4071-2014-5-35-42.Vatutin N.T., Taradin G.G., Maron M.S. Hypertrophic cardiomyopathy: Genetic changes, pathogenesis and pathophysiology. Russian Journal of Cardiology. 2014;(5):35–42. (In Russ.) DOI: 10.15829/1560-4071-2014-5-35-42.Соничева Н.А., Затейщиков Д.А. Кардиология: время генетики. Consilium Medicum. 2020;5(22):35–39. DOI: 10.26442/20751753.2020.5.200185.Sonicheva N.A., Zateyshchikov D.A. Cardiology: Genetics’ time. Consilium Medicum. 2020; 5(22):35–39. (In Russ.). DOI: 10.26442/20751753.2020.5.200185.Сейдалин А.О., Альбазаров А.Б., Тожибоев Р.Э., Нуракаева С.С., Сыгай А.И., Диколаев В.Д. Хирургическое лечение обструктивной гипертрофической кардиомиопатии. Клиническая медицина Казахстана. 2015;1(35). URL: https://cyberleninka.ru/article/n/hirurgicheskoe-lechenie-obstruktivnoy-gipertroficheskoy-kardiomiopatii.Seidalin A.O., Albazarov A.B., Tojiboyev R.E., Nuracaeva S.S., Sugai A.I., Dicolaev V.D. Surgical treatment of an obstructive hypertrophic cardiomyopathy. Clinical Medicine in Kazakhstan. 2015;1(35). (In Russ.). URL: https://cyberleninka.ru/article/n/hirurgicheskoe-lechenie-obstruktivnoy-gipertroficheskoy-kardiomiopatii.Богачев-Прокофьев А.В., Железнев С.И., Фоменко М.С., Шарифулин Р.М., Афанасьева А.В., Малахова О.Ю. и др. Эффективность расширенной миоэктомии у пациентов с желудочковой обструкцией при гипертрофической кардиомиопатии. Кардиология. 2017;57(5):38–43. DOI: 10.18565/cardio.2017.5.38-43.Bogachev-Prokophiev A.V., Zheleznev S.I., Fomenko M.S., Sharifulin R.M., Afanasieva A.V., Malahova O.Yu. et al. Effectiveness of extended myectomy in patients with hypertrophic cardiomyopathy with midventricular obstruction. Cardiology. 2017;57(5):38–43. (In Russ.). DOI: 10.18565/cardio.2017.5.38-43.Wehman B., Ghoreishi M., Foster N., Wang L., D’Ambra M.N., Maassel N. et al. Transmitral septal myectomy for hypertrophic obstructive cardiomyopathy. Ann. Thorac. Surg. 2018;105(4):1102–1108. DOI: 10.1016/j.athoracsur.2017.10.045.Wehman B., Ghoreishi M., Foster N., Wang L., D’Ambra M.N., Maassel N. et al. Transmitral septal myectomy for hypertrophic obstructive cardiomyopathy. Ann. Thorac. Surg. 2018;105(4):1102–1108. DOI: 10.1016/j.athoracsur.2017.10.045.Чумакова О.С. Гипертрофическая кардиомиопатия у пожилых: причины, диагностика, лечение. Терапевтический архив. 2020;92(9):63–69. DOI: 10.26442/00403660.2020.09.000558.Chumakova O.S. Hypertrophic cardiomyopathy in elderly: Causes, diagnostic and treatment approaches. Terapeutic Archiv. 2020;92(9):63–69. (In Russ.). DOI: 10.26442/00403660.2020.09.000558.Осиев А.Г., Гегенава Б.Б., Палеев Ф.Н., Григорьева Н.М. Спиртовая септальная абляция межжелудочковой перегородки с контрастным эхокардиографическим контролем. Российский кардиологический журнал. 2017;(8):122–127. DOI: 10.15829/1560-4071-2017-8-122-127.Osiev A.G., Gegenava B.B., Paleev F.N., Grigoryeva N.M. Alcohol-based septal ablation of interventricular septum with contrast echocardiographic control. Russian Journal of Cardiology. 2017;(8):122–127. (In Russ.). DOI: 10.15829/1560-4071-2017-8-122-127.Sorajja P., Valeti U., Nishimura R., Ommen S., Rihal Ch., Gersh B. et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008;118(2):131–139. DOI: 10.1161/CIRCULATIONAHA.107.738740.Sorajja P., Valeti U., Nishimura R., Ommen S., Rihal Ch., Gersh B. et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008;118(2):131–139. DOI: 10.1161/CIRCULATIONAHA.107.738740.Olivotto I., Ho C., Jacoby D., Lester S., Roe M., Wang A. et al. Abstract 16466: EXPLORER-HCM: Phase 3 Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy. Circulation. 2018;138:A16466. DOI: 10.1161/circ.138.suppl_1.16466.Olivotto I., Ho C., Jacoby D., Lester S., Roe M., Wang A. et al. Abstract 16466: EXPLORER-HCM: Phase 3 Randomized, Multi-Center, Double- Blind, Placebo-Controlled Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy. Circulation. 2018;138:A16466. DOI: 10.1161/circ.138.suppl_1.16466.Heitner S.B., Jacoby D., Lester S.J., Owens A., Wang A., Zhang D. et al. Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial. Ann. Intern. Med. 2019;170(11):741–748. DOI: 10.7326/m18-3016.Heitner S.B., Jacoby D., Lester S.J., Owens A., Wang A., Zhang D. et al. Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial. Ann. Intern. Med. 2019;170(11):741–748. DOI: 10.7326/m18-3016.Ho C.Y., Mealiffe M.E., Bach R.G., Bhattacharya M., Choudhury L., Edelberg J.M. et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J. Amer. Coll. Card. 2020;75(21):2649–2660. DOI: 10.1016/j.jacc.2020.03.064.Ho C.Y., Mealiffe M.E., Bach R.G., Bhattacharya M., Choudhury L., Edelberg J.M. et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J. Amer. Coll. Card. 2020;75(21):2649–2660. DOI: 10.1016/j.jacc.2020.03.064.Olivotto I., Oreziak A., Barriales-Villa R., Abraham T.P., Masri A., Garcia-Pavia P. et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;369(10253):759–769. DOI: 10.1016/S0140-6736(20)31792-X.30.Olivotto I., Oreziak A., Barriales-Villa R., Abraham T.P., Masri A., Garcia- Pavia P. et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;369(10253):759–769. DOI: 10.1016/S0140-6736(20)31792-X.30.Jacoby D., Ho C.Y., Lester S.J., Wang A., Olivotto I. Mavacamten for hypertrophic obstructive cardiomyopathy – Authors’ rely. Lancet. 2021;397(10272):369–370. DOI: 10.1016/s0140-6736(20)32391-6.Jacoby D., Ho C.Y., Lester S.J., Wang A., Olivotto I. Mavacamten for hypertrophic obstructive cardiomyopathy – Authors’ rely. Lancet. 2021;397(10272):369–370. DOI: 10.1016/s0140-6736(20)32391-6.Quintana E., Bajona P., Myers P.O. Mavacamten for hypertrophic obstructive cardiomyopathy. Lancet. 2021;397(10272):369. DOI: 10.1016/S0140-6736(20)32384-9.Quintana E., Bajona P., Myers P.O. Mavacamten for hypertrophic obstructive cardiomyopathy. Lancet. 2021;397(10272):369. DOI: 10.1016/S0140-6736(20)32384-9.

The authors declare that there are no conflicts of interest present.